A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Trial Profile

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs MSC 2363318A (Primary) ; Tamoxifen; Trastuzumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 31 Aug 2018 to 8 Jul 2018.
    • 09 Apr 2018 Planned primary completion date changed from 31 Aug 2018 to 8 Jul 2018.
    • 10 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top